| Ticker Symbol: | SPPI |
|---|---|
| Exchange: | NASD |
| Contact Info: | 157 Technology Drive Irvine CA 92618 949 788-6700 |
| CEO/President: | Rajesh C. Shrotriya M.D. |
| Industry: | Medical - Drugs / Standard Industry Code: 2834 |
| Description: | Spectrum Pharmaceuticals, Inc. is opportunistically acquiring and advancing a diversified portfolio of oncology drug candidates that meet critical health challenges for which there are few other treatment options. Spectrum\'s expertise lies in identifying undervalued drugs with demonstrated safety and efficacy, and adding value through further clinical development and selection of the most viable and low-risk methods of commercialization. The company\'s pipeline includes promising early and late-stage drug candidates with unique formulations and mechanisms of action that address the needs of seriously ill patients, such as at-home chemotherapy and new treatment regimens for refractory disease. |
| Shares Outstanding: | 31,510 (000) | Market Value: | 42,540 ($000) |
|---|---|---|---|
| Percentage of Inst.Shareholders: | 42.41% | Number of Inst.Shareholders: | 12.30% |
| Last Quarter Sales: | 0.00 ($Mil.) | Last Quarter Net Income: | -8.82 ($Mil.) |
| Last Quarter EPS: | -0.28 | P/E Ratio: | 0 |
| Most Recent Earnings: | Earnings Per Share: | -0.63 | |
| Most Recent Split: | Annual Dividend Rate: | 0 | |
| Most Recent Dividend: | Annual Dividend Yield: | 0% |


| PFIZER INC | -30.60 | 15.56 | |
| JOHNSON AND JOH | -15.60 | 58.12 | |
| BRISTOL MYERS S | -21.10 | 20.27 | |
| SCHERING PLOUGH | -43.00 | 15.35 | |
| MERCK CO INC | -56.80 | 25.31 |
